Estonia - Esti - Ravimiamet

krka, d.d., novo mesto - losartaan+amlodipiin - õhukese polümeerikattega tablett - 50mg+5mg 10tk; 50mg+5mg 60tk; 50mg+5mg 56tk; 50mg+5mg 28tk; 50mg+5mg 84tk

Estonia - Esti - Ravimiamet

kalceks as - oksükodoon - süste-/infusioonilahus - 50mg 1ml 1ml 5tk

Estonia - Esti - Ravimiamet

kalceks as - oksükodoon - süste-/infusioonilahus - 10mg 1ml 1ml 5tk; 10mg 1ml 2ml 5tk; 10mg 1ml 1ml 25tk; 10mg 1ml 2ml 10tk; 10mg 1ml 1ml 10tk

Estonia - Esti - Ravimiamet

krka, d.d., novo mesto - losartaan+amlodipiin - õhukese polümeerikattega tablett - 50mg+10mg 84tk; 50mg+10mg 28tk; 50mg+10mg 10tk; 50mg+10mg 30tk; 50mg+10mg 56tk

Estonia - Esti - Ravimiamet

krka, d.d., novo mesto - losartaan+amlodipiin - õhukese polümeerikattega tablett - 100mg+5mg 84tk; 100mg+5mg 90tk; 100mg+5mg 30tk; 100mg+5mg 60tk

Estonia - Esti - Ravimiamet

krka, d.d., novo mesto - losartaan+amlodipiin - õhukese polümeerikattega tablett - 100mg+10mg 30tk; 100mg+10mg 90tk; 100mg+10mg 56tk; 100mg+10mg 60tk

Estonia - Esti - Ravimiamet

fresenius kabi oncology plc - fludarabiin - süste-/infusioonilahuse pulber - 50mg 50mg 1tk

Uni Eropa - Esti - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaktsiinid - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Uni Eropa - Esti - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekursorko-lümfoblastne leukeemia-lümfoom - antineoplastilised ained - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Uni Eropa - Esti - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastilised ained - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.